LGC acquires Axolabs and invests in GMP manufacturing capacity for therapeutic nucleic acids
News - Moves strengthen existing analytical and bioanalytical drug development service offering
03 April 2017
Research clarifies carry-over contamination risk during GMP production of minced meat
News - Establishes there should be no detectable carry-over contamination when producing minced meat in accordance with GMP
17 June 2014
LGC invests in new GMP analytical capability
News - The new labs comprise additional bioanalysis and synthetic chemistry labs as well as a new GMP CMC analytical capability for batch release testing of oligonucleotide-based drug substances
01 October 2018
LGC and Aptahem combine on first large-scale production campaign of Apta-1
News - First large-scale production run of Apta-1as a non-GMP material, intended for use in GLP toxicology studies
13 August 2020
LGC to develop new Berlin site to expand Nucleic Acid Therapeutics capacity
News - Site will be dedicated to medium to large scale and early to late Phase Clinical GMP manufacturing of Nucleic Acid Therapeutics
15 November 2021